Format

Send to

Choose Destination
Eur J Hosp Pharm Sci Pract. 2017 Jul;24(4):224-229. doi: 10.1136/ejhpharm-2016-001016. Epub 2016 Sep 5.

Legislation on the preparation of medicinal products in European pharmacies and the Council of Europe Resolution.

Author information

1
Ministry of Health, Welfare and Sport, Health Care Inspectorate, Utrecht, The Netherlands.
2
Department of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.
3
Capital Region Pharmacy, Herlev, Denmark.
4
European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, Strasbourg, France.
5
Pharmaceutical law University of Utrecht, Utrecht, The Netherlands.
6
Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, The Netherlands.
7
CAPHRI School for Public Health and Primary Care, Maastricht, The Netherlands.

Abstract

Introduction:

The rights of patients should be sufficiently protected even when an appropriate authorised medicine does not exist or is unavailable on the market. The Resolution, which was adopted by the Committee of Ministers of the Council of Europe in 2011, aims at harmonising quality and safety standards for pharmacy preparation of medicinal products in Europe.

Two pillars of EU regulation and the exceptions to them:

The system of regulation of medicinal products is built upon two pillars: the marketing authorisation of the medicinal product and the licence for manufacturing and wholesale. This article provides insight into the recent interpretation of the European Court of Justice concerning the scope of European Union (EU) regulation of medicinal products and the circumstances in which the EU regulation does not apply: pharmacy preparations, specialties and the compassionate use of medicines, including manufacturing licence.

EU regulation and the Resolution concerning pharmacy preparation:

Pharmacy preparations are allowed under certain strict conditions according to EU regulations. However, pharmacies specialised in preparation and distributing medicinal products to local pharmacies do not fulfil these strict conditions in EU regulation. Apart from the legal context, relevant standards for safety and quality assurance are needed in Europe in order to protect patients' rights and to avoid risks from pharmacy preparations.

Discussion and conclusions:

The Council of Europe Resolution provides a means of establishing standards for safety and quality assurance for pharmacy preparations through Good Manufacturing Practice Guidelines. The Resolution is available to authorities and pharmacists in order to prevent incidents with medicines prepared in pharmacies which may threaten patients' safety. The authors conclude that pharmacy practices have changed over time in Europe and this may imply a reason for a reform of EU regulation on medicinal products.

KEYWORDS:

Council of Europe Resolution ResAP(2011)1; EU regulation; European Court of Justice; Patient safety; Pharmacy preparations

Supplemental Content

Full text links

Icon for BMJ Publishing Group Icon for PubMed Central
Loading ...
Support Center